BLSM
HOLD / NEUTRALNeutralComposite
47.10
Technical
46.10
Fundamental
47.70
Rank
—
Price
15.99
Hurst
—
As of
Aug 11, 2026
Daily
BlossomHill Therapeutics, Inc.
HealthcareBiotechnologyBlossomHill Therapeutics is a clinical-stage drug developer focused on creating small molecule treatments for cancer. The company's lead candidates include BH-30643, targeting advanced lung cancer with EGFR mutations, and BH-30236, a CLK inhibitor being tested in patients with treatment-resistant blood cancers including acute myeloid leukemia and myelodysplastic syndrome. Founded in 2020 and headquartered in San Diego, the company operates in the biopharmaceutical sector.
Market cap
$780.0M
P/E (trailing)
—
P/E (forward)
-7.22
PEG ratio
—
Dividend yield
—
Beta
—
52w range
15.25 – 27.80
Return on equity
—
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 26.25 (+64.1%) · range 15.80–26.25
Cycle position
91/ 100 cycle scoreEXIT ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 0 · NOT READY · exit proximity 100
Conviction
18/ 100 · maturity 0%
Buildup.3318
EMA entry setup.420
Fundamentals.2548
Volume profile
POC
16.32
Price vs POC
+60.9%
Overhead supply
1%
Runway
open sky
Value area 15.25–18.57 · 1% of 28d volume overhead · clean runway
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +33.17% | +38.80% | mature |
| 40d | +26.27% | +38.80% | 22/40d |